ReviewNature reviews. Drug discovery2010
Developing drug prototypes: pharmacology replaces safety and tolerability?
Review in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Pharmacodynamic response profiles of anxiolytic and sedative drugs.British journal of clinical pharmacology · 2017Trial
- Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.British journal of clinical pharmacology · 2013Trial
- Pain Research and Treatment: Policy Implications.Policy insights from the behavioral and brain sciences · 2024Article
- Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.International journal of molecular sciences · 2021Review
- Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.Toxins · 2018Article
- Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects.British journal of clinical pharmacology · 2018Review
- Pharmacological vs. classical approaches in the design of first in man clinical drug trials.British journal of clinical pharmacology · 2017Article
- Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.European journal of clinical pharmacology · 2017Review
- EEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease.Scientific reports · 2017Article
- Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model.Journal of clinical psychopharmacology · 2016Article
- Implications of the BIA-102474-101 study for review of first-into-human clinical trials.British journal of clinical pharmacology · 2016Article
- Industrialized research in the BJCP: a neo-Luddite view.British journal of clinical pharmacology · 2012Article
- Animal models and conserved processes.Theoretical biology & medical modelling · 2012Article
- Translating discoveries into medicine: psychiatric drug development in 2011.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- Medicinal chemistry for 2020.Future medicinal chemistry · 2011Article
- Vanishing clinical psychopharmacology.British journal of clinical pharmacology · 2011Article
- The institutional review board is an impediment to human research: the result is more animal-based research.Philosophy, ethics, and humanities in medicine : PEHM · 2011Article
- From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.The AAPS journal · 2011Article
- More on first-in-man studies.British journal of clinical pharmacology · 2010Article
- Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.Innovations in clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New medicines are designed to bind to receptors or enzymes and are tested in animal cells, tissues and whole organisms in a highly scientific process. Subsequently they are often administered to human subjects with tolerability as the primary objective. The process of development is considered to be linear and consecutive and passes through the famous four phases of development (Phase I-Phase IV). This is efficient for those projects for which the uncertainty about the development is low. There is, however, an increasing number of new prototypical compounds resulting from the increased biological knowledge with a high level of uncertainty. For these prototypical drugs development has to proceed in a much more adaptive manner, using tailor-made objectives, the development of special methodology and a cyclical rather than a linear type of project management.
Indexed as
Identifiers
20847743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.